Impact of tuberculosis treatment length and adherence under different transmission intensities

Theoretical Population Biology

Volumn 104, Issue , 2015, Pages 68-77

  Pinho, S T R ^a   Rodrigues, P ^b   Andrade, R F S ^a   Serra, H ^c   Lopes, J S ^d   Gomes, M G M ^d  

^a FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^b UNIVERSIDADE NOVA DE LISBOA   (Portugal)

^c UNIVERSIDADE FEDERAL DA GRANDE DOURADOS   (Brazil)

^d INSTITUTO GULBENKIAN DE CIÊNCIA   (Portugal)

Author keywords

Default; Mathematical model; Reinfection; Treatment; Tuberculosis

Indexed keywords

DATA SET; DISEASE TRANSMISSION; DISEASE TREATMENT; EPIDEMIOLOGY; HEALTH RISK; INFECTIOUS DISEASE; NUMERICAL MODEL; TUBERCULOSIS;

TUBERCULOSTATIC AGENT;

BIOLOGICAL MODEL; DRUG ADMINISTRATION; HUMAN; MEDICATION COMPLIANCE; TRANSMISSION; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; DRUG ADMINISTRATION SCHEDULE; HUMANS; MEDICATION ADHERENCE; MODELS, BIOLOGICAL; TUBERCULOSIS;

EID: 84939550643     PISSN: 00405809     EISSN: 10960325     Source Type: Journal    
DOI: 10.1016/j.tpb.2015.06.004     Document Type: Article

References (26)

1. Abu-Raddad L.J., Sabatelli L., Achterberg J.T., Sugimoto J.D., Longini I.M., Dye C., Halloran M.E. Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics. Proc. Natl. Acad. Sci. 2009, 106:13980-13985.
2. Alliance T.B. Confronting TB: What it takes, 2008 Annual Report 2008, Global Alliance for TB Drug Development, New York.
3. Borgdorff M.W., Veen J., Kalisvaart N.A., Broekmans J.F., Nagelkerke N.J.D. Defaulting from tuberculosis treatment in the Netherlands: rates, risk factors and trend in the period 1993-1997. Eur. Respir. J. 2000, 16:209-213.
4. Cohen T., Coljin C., Finklea B., Murray M. Exogenous re-infection and the dynamics of tuberculosis epidemics: Local effects in a network model of transmission. J. R. Soc. Interface 2007, 4:523-531.
5. Coljin C., Cohen T., Murray M. Emergent heterogeneity in declining tuberculosis epidemics. J. Theor. Biol. 2007, 247:765-774.
6. Dye Christopher, Garnett Geoffrey P., Sleeman Karen, Williams Brian G. Prospects for worldwide tuberculosis control under the WHO DOTS strategy. Lancet 1998, 352:1886-1891.
7. Frieden T.R., Sterling T.R., Munsiff S.S., Watt C.J., Dye C. Tuberculosis. Lancet 2003, 362:887-899.
8. Gomes M.G.M., Águas R., Lopes J.S., Nunes M.C., Rebelo C., Rodrigues P., Struchiner C.J. How host heterogeneity governs tuberculosis reinfection. Proc. R. Soc. B 2012, 279:2473-2478.
9. Gomes M.G.M., Franco A.O., Gomes M.C., Medley G.F. The reinfection threshold promoted variability in tuberculosis epidemiology and vaccine efficacy. Proc. R. Soc. B 2004, 271:617-623.
10. Gomes M.G.M., Rodrigues P., Hilker F., Mantilla-Beniers N.B., Muehlen M., Paulo A., Medley G.F. Implications of partial immunity on the prospects for tuberculosis control by post-exposure interventions. J. Theoret. Biol. 2007, 248:608-617.
11. Gomes M.G.M., White L.J., Medley G.F. Infection, reinfection, and vaccination under suboptimal immune protection: epidemiological perspectives. J. Theor. Biol. 2004, 235(2):151-152.
12. Hasker E., Khodjikhanov1 M., Usarova S., Asamidinov U., Yuldashova U., J van der Werf M., Uzakova G., Veen J. Default from tuberculosis treatment in Tashkent, Uzbekistan; Who are these defaulters and why do they default?. BMC Infect. Dis. 2008, 8:97.
13. Jha U.M., Satayanarayana S., Dewan P.K., Chadha S., Wares F., Sahu S., Gupta D., Chauhan L.S. Risk factors for treatment default among re-treatment tuberculosis patients in India, 2006. PLoS One 2010, 5:e8873.
14. Khan M.S., Khan S., Godfrey-Faussett P. Default during TB diagnosis: quantifying the problem. Trop. Med. Int. Health. 2009, 14:1437-1441.
15. Kruk M.E., Schwalbe N.R., Aguiar C.A. Timing of default from tuberculosis treatment: a systematic review. Trop. Med. Int. Health. 2008, 13:703-712.
16. Lopes J.S., Rodrigues P., Pinho S.T.R., Andrade R.F.S., Duarte R., Gomes M.G.M. Interpreting simple measures of tuberculosis transmission: a case study on the Portuguese population. BMC Infect. Dis. 2014, 14:340.
17. Munro S.A., Lewin S.A., Smith H.J., Engel M.E., Fretheim A., Volmink J. Patient adherence to tuberculosis treatment: A systematic review of qualitative research. PLoS Med. 2007, 4(7):1230-1245.
18. O'Brien R.J., Spigelman M. New drugs for tuberculosis: Current status and future prospects. Clin. Chest Med. 2005, 26:327-340.
19. Rodrigues P. Modeling tuberculosis: a compromise between biological realism and mathematical tractability 2009, (Ph.D. thesis), University of Lisbon.
20. Salomon J.A., Lloyd-Smith J.O., Getz W.M., Resch S., Sánches M.S., Porco T.C., Borgdorff M.W. Prospects for advancing tuberculosis control efforts through novel therapies. PLoS Med. 2006, 3:1302-1309.
21. Shargie E.B., Lindtjorn B. Determinants of treatment adherence among smear-positive pulmonary tuberculosis patients in Southern Ethiopia. PLoS Med. 2007, 4:e37.
22. Small P.M., Fujiwara M.D. Management of tuberculosis in the United States. N. Engl. J. Med. 2001, 345(3):189-200.
23. Souza M.S.P.L., Pereira S.M., Marinho J.M., Barreto M.L. Characteristics of healthcare services associated with adherence to tuberculosis treatment. Rev. Saúde Pública 2009, 43:1-8.
24. van den Driessche P., Watmough J. Reproduction numbers and sub-threshold endemic equilibria for compartmental models of disease transmission. Math. Biosci. 2002, 180:29-48.
25. Vynnycky E., Fine P.E.M. The natural history of tuberculosis: the implications of age-dependent risks of disease and the role of reinfection. Epidemiol. Infect. 1997, 119:183-201.
26. WHO, 2008. The Stop strategy-building on and enhancing DOTS to meet the TB-related Millennium Development Goals. WHO/HTM/TB/2006.368.